2024-04-27
![](/wp-content/uploads/2023/02/Arbele-logo-full.png)
Arbele announces early safety data for novel CDH17xCD3 bispecific T-cell engager at American Society of Clinical Oncology Breakthrough Meeting
2023-05-05
![](/wp-content/uploads/2023/06/20230505-154259_1_l.jpg)
Arbele celebrates its 7th anniversary as a clinical-stage immunotherapy biotech and the opening of TibTech, its cancer diagnostics subsidiary
2022-08-10
![](/wp-content/uploads/2023/06/20220811-043106_1_l.jpg)
Arbele Announces Phase 1 First-in-Human Study of CDH17xCD3 Bispecific T-Cell Engager for Treatment of Gastrointestinal Cancers
2021-05-01
![](/wp-content/uploads/2023/06/20210712-020510_1_l.jpg)
Global Business Leaders Magazine
2021-02-02
![](/wp-content/uploads/2023/06/20220225-171550_1_l.jpg)
雙抗體免疫治療 腸胃癌治療的未來方向
2021-01-26
![](/wp-content/uploads/2023/06/20220225-170406_1_l.jpg)
對付腸胃癌 免疫治療成趨勢
2020-10-12
![](/wp-content/uploads/2023/06/20201014-163151_1_l.jpg)
StartupBeat Policy: 創科界籲政策扶持勿只派錢
2020-10-12
![](/wp-content/uploads/2023/06/20201014-164406_1_l.jpg)
Arbele Newsletter Oct-2020 (Issue No.2)
2020-06-11
![](/wp-content/uploads/2023/02/Arbele-logo-full.png)
Avalon GloboCare Announces Three-Way Material Transfer Agreement with Weill Cornell Medicine and Arbele Limited for Development of Next Generation Cellular Immunotherapy FLASH-CAR(TM) Technology
2020-06-10
![](/wp-content/uploads/2023/06/20200624-103817_1_l.jpg)
Arbele Newsletter